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Prior immunization of hamsters with three heterologous flaviviruses (Japanese encephalitis virus [JEV]
SA14-2-8 vaccine, wild-type St. Louis encephalitis virus [SLEV], and Yellow fever virus [YFV] 17D vaccine)
reduces the severity of subsequent West Nile virus (WNV) infection. Groups of adult hamsters were immu-
nized with each of the heterologous flaviviruses; approximately 30 days later, the animals were injected
intraperitoneally with a virulent New York strain of WNV. Subsequent levels of viremia, antibody response,
and deaths were compared with those in nonimmune (control) hamsters. Immunity to JEV and SLEV was
protective against clinical encephalitis and death after challenge with WNV. The antibody response in the
sequentially infected hamsters also illustrates the difficulty in making a serologic diagnosis of WNV infec-
tion in animals (or humans) with preexisting Flavivirus immunity. 
est Nile virus (WNV) was detected for the first time in
North America in summer of 1999, during an outbreak
involving humans, equines, and birds in the New York City
metropolitan area (1). Persistence of the virus and its spread to
other states on the eastern seaboard during 2000 and 2001 sug-
gest that WNV is now endemic in the United States and that its
geographic range probably will continue to expand until it
extends over much of the continent (2). Although many WNV
infections in humans are asymptomatic or unrecognized, some
patients have an acute dengue-like illness, and a small percent-
age have encephalitis or meningoencephalitis (1-5). The latter
complication is most common among the elderly, with recent
reported case-fatality rates from 4% to 11% (3-9). No specific
treatment is available for WNV encephalitis, and no licensed
vaccine is available for its prevention. 
WNV is a positive-stranded RNA virus; based on its anti-
genic and genetic characteristics, it is included in the Japanese
encephalitis virus (JEV) serocomplex of the genus Flavivirus,
family Flaviviridae (10). The JEV serocomplex includes four
antigenically related viruses that are important causes of
encephalitis in humans: JEV, WNV, St. Louis encephalitis
virus (SLEV), and Murray Valley encephalitis virus (MVEV).
In addition to their antigenic and genetic relatedness, these
four viruses have many epidemiologic similarities (3,11).
Because of the close antigenic relationships among many
viruses in this genus, Flavivirus infections are difficult to dif-
ferentiate by most serologic techniques, especially in persons
or animals having a second or sequential Flavivirus infection
(12-14). Considerable attention has been focused on the
immune response in primary and secondary Flavivirus infec-
tion and the role of immunopathogenesis in the etiology of
severe Flavivirus disease (11,15,16). In the case of dengue,
enhancement of virus replication by heterologous flavivirus
antibodies and T-cell activation are thought to occur in some
patients during a second or sequential dengue infection, result-
ing in hemorrhagic fever or shock (15,16). In contrast, animal
data indicate that prior infection with a heterologous Flavivi-
rus reduces the severity of subsequent challenge with WNV.
Results of experimental studies with rodents, monkeys, and
pigs (17-21) suggest that heterologous Flavivirus antibodies
protect against or modify subsequent infection with WNV.
This phenomenon could be important in vaccine development
against WNV infection and in determining the ultimate geo-
graphic distribution and public health importance of WNV if it
is introduced into areas of Central and South America where
other flaviviruses, such as Dengue virus (DENV), Yellow fever
virus (YFV), SLEV, and Ilhéus virus (ILHV), are endemic. 
To determine more precisely the degree of cross-protection
among members of the JEV serocomplex and the possibility
that this phenomenon could be used to protect against severe
WNV infection, a series of experiments was carried out with
three heterologous flaviruses and a recently described model
(22) of WNV encephalitis. We report the results of these stud-
ies, which indicate that prior immunization of hamsters with a
JEV vaccine strain and a wild-type SLEV—and to a lesser
extent the 17-D YFV vaccine—modify subsequent WNV
infection and protect the animals from fatal encephalitis. 
Materials and Methods
Four flaviviruses were used in this study: WNV strain 385-
99, isolated from a dead snowy owl at the Bronx Zoo during
the 1999 epizootic in New York City (23); live attenuated
SA14-2-8 vaccine strain of JEV (24,25); 17-D live attenuated
vaccine strain of YFV (26); and SLEV strain Be Ar 23379 *University of Texas Medical Branch, Galveston, Texas, USA
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(27), originally isolated from mosquitoes (Sabethes belisarioi)
in Para, Brazil, in 1961. 
The hamsters used in our studies were adult (70 g to 100 g)
female Syrian golden hamsters (Mesocricetus auratus) (Har-
lan Sprague Dawley, Indianapolis, IN). Animals were cared
for in accordance with the guidelines of the Committee on
Care and Use of Laboratory Animals (Institute of Laboratory
Animal Resources, National Research Council) under an ani-
mal use protocol approved by the University of Texas Medical
Branch. All work with infected animals was carried out in bio-
safety level-3 facilities.
All virus titrations were done in cultures of the C6/36
clone of Aedes albopictus cells (28), with the presence or
absence of viral antigen by immunofluorescence as the end-
point, as described (22,29,30). To determine the quantity of
infectious virus in blood samples taken daily after WNV infec-
tion, each hamster blood specimen was titrated in 24-well tis-
sue culture plates seeded with C6/36 cells. Serial 10-fold
dilutions from 10-1 to 10-7 were made of each sample in phos-
phate-buffered saline, pH 7.4 (PBS), containing 10% fetal
bovine serum; 0.1 mL of each dilution was added to four wells
of a tissue culture plate. Following absorption at 28°C for 2
hours, 1.5 mL of maintenance medium (29) was added to each
well, and the plates were incubated at 28°C in a 5% CO2 atmo-
sphere for 6 days. On day 6, 20 mL of a cell suspension from
each well was added to a single spot on 12-spot glass micro-
scope slides (Cell-Line Associates, Inc., Newfield, NJ). After
drying at room temperature, the slides were immersed in cold
acetone for 10 minutes; the cells were subsequently examined
for the presence of WNV antigen by indirect fluorescent anti-
body test by using a WNV-specific mouse immune ascitic
fluid (see below) and a commercially prepared fluorescein-
conjugated, goat antimouse immunoglobulin (Sigma, St.
Louis, MO). WNV titers were calculated as the tissue culture
infectious dose50 (TCID50) per mL of specimen by the method
of Reed and Muench (31). 
Experimental Infection of Animals
Hamsters were infected by the intraperitoneal (IP) or sub-
cutaneous (SC) routes, depending on the virulence of the
infecting virus for the animals. WNV and YFV were injected
IP; JEV and SLEV were administered SC. Infecting doses of
the viruses were as follows: WNV 104.0 TCID50, YFV 106.0
TCID50, JEV 106.5 TCID50, and SLEV 106.0 TCID50. 
Immune Reagents
A mouse immune ascitic fluid to WNV was prepared in
adult mice. The immunogen was a crude homogenate of brain
(10% W/V in PBS) from newborn mice injected intracere-
brally (IC) with the B956 prototype strain of WNV (32). The
adult immunization schedule consisted of four IP injections of
the immunogen mixed with Freund’s adjuvant, given at
weekly intervals. Sarcoma 180 cells were given after the final
injection to induce ascites formation. 
Antibody Determinations
Serum antibodies to WNV and the other three flaviviruses
were measured by hemagglutination-inhibition (HI) test and to
WNV by immunoglobulin (Ig) M antibody capture enzyme
immunoassay (MAC-ELISA) (33). Antigens for both sero-
logic tests were prepared from brains of newborn mice
injected IC with each of the flaviviruses; the infected brains
were treated by the sucrose-acetone extraction method (33).
Hamster sera were tested by HI at serial twofold dilutions from
1:20 to 1:5120 at pH 6.6 (WNV, JEV, and SLEV) or 6.4 (YFV)
with 4 units of antigen and a 1:200 dilution of goose erythro-
cytes, following established protocols (33). 
For the MAC-ELISA, microtiter plates were coated with a
commercial goat anti-rat IgM (capture) antibody (Kirkegaard
& Perry Laboratories, Inc., Gaithersburg, MD), diluted 1:500
in carbonate buffer, pH 9.6. All hamster sera were screened at
a 1:40 dilution. The WNV antigen was also used at a 1:40 dilu-
tion. The secondary (detecter) antibody was a mouse, anti-Fla-
vivirus, peroxidase-conjugated monoclonal antibody (6B6C-1)
at a dilution of 1:6000. Results were read with a SPECTRA
shell reader (SLT Labininstruments, Salzburg, Austria). Speci-
mens wells were recorded as positive when the absorbance
values at optical density405 nm of the specimen wells
exceeded 0.20 after subtraction of average background absor-
bance of control wells (33). 
Results
Infection of Nonimmune Hamsters with WNV
Several groups of Flavivirus-naive (control) hamsters were
inoculated IP with 104 TCID50 of WNV to determine the sub-
sequent level and duration of viremia, immune response, and
death rate. Table 1 and the Figure show the results of an exper-
iment with a group of 10 hamsters that were bled daily for 6
consecutive days after infection with WNV. Moderate levels of
virus were detected in the animals’ blood within 24 hours and
persisted for 5 or 6 days. The highest blood virus titers were
detected on days 2 and 3 after infection (means 105.2 and
105.1, respectively). HI antibodies were detected in all the ani-
mals by day 5, and the titers had increased substantially by day
6. In general, WNV-specific IgM, as detected by MAC-
ELISA, appeared at approximately the same time as the HI
antibodies (data not shown). 
Table 2 shows the results of a second experiment in which
13 hamsters were infected with WNV. All the animals were
bled 6 days after injection, and a subset was bled again at 31,
60, and 90 days. Six days after infection, all the animals had
specific HI antibodies to WNV antigen and were negative to
the other three flaviviral antigens tested (YFV, SLEV, and
JEV). At this time, the animals also had a strongly positive
IgM antibody response by MAC-ELISA. Thirty-one days after
infection, the HI antibody response had become broadly cross-
reactive with the four Flavivirus antigens, although the highest
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decrease. A similar HI antibody pattern was observed at 60
and 90 days after infection, although by 90 days the HI titers
were decreasing. Six of the nine WNV-infected hamsters gave
a negative reaction in the WNV MAC-ELISA when tested 60
and 90 days after infection. 
Five of the 13 hamsters infected in this second experi-
ment died of WNV encephalitis 7 to 14 days after infection
(Table 2). Overall, 14 (47%) of 30 adult hamsters injected IP
with 104 TCID50 of WNV died of encephalitis (Table 3). The
pathologic reaction of the WNV hamster model has been
described (22). 
Infection of JEV-Immune Hamsters with WNV
The Figure and Table 4 show the results from another
experiment in which 30 adult hamsters were given a single SC
injection of approximately 106.4 TCID50 of the live attenuated
JEV SA14-2-8 vaccine strain. Thirty-eight days later, the ani-
mals were injected (challenged) IP with 104 TCID50 of WNV;
10 of the hamsters in this group were bled daily for 6 consecu-
tive days. These blood samples were subsequently titrated to
determine the level of WNV viremia. The resulting viremia in
the JEV-immune animals was markedly lower than in the
naïve hamsters (Figure). Furthermore, the JEV-immune ham-
sters responded to challenge with WNV by developing a sec-
ondary (sequential) type of Flavivirus antibody response.
Table 4 shows the HI antibody titers to JEV and WNV anti-
gens in sera of 10 of the SA14-2-8 vaccinated hamsters, 30
days after their JEV immunization. At this time the HI anti-
body titers to JEV and WNV antigens were characteristic of a
primary Flavivirus infection (13,14). On day 38, the animals
were challenged with WNV; 6 days later, their sera were tested
for HI and WNV-specific IgM antibodies. The boost in HI
antibody titers that was observed 6 days after challenge with
WNV was typical of a secondary antibody response to Flavivi-
rus infection (13,14). In contrast, IgM antibody response to the
second Flavivirus (WNV) infection was minimal (Table 4). 
All the JEV-immune hamsters (n = 30) survived challenge
with WNV (Table 3). Their infection with WNV was con-
firmed by the presence of low-level viremia (Figure) and the
secondary Flavivirus antibody response following challenge
(Table 4). None of these hamsters appeared clinically ill after
infection with WNV, in contrast to the naïve animals. Many of
the nonimmune hamsters had clinical signs of acute central
nervous system injury (somnolence, muscle weakness, paraly-
sis, tremors, and loss of balance) beginning around day 6 after
infection, and approximately half died (22). Thus, prior immu-
nization with JEV vaccine reduced the severity of subsequent
WNV infection and prevented death. 
Table 1. Pattern of viremia and hemagglutination inhibition (HI) antibody response in 10 adult Flavivirus-naïve (control) hamsters, following intra-
peritoneal inoculation of 104 TCID50 of West Nile virus (WNV) 
Animal No.
Day postinoculation
D-1 D-2 D-3 D-4 D-5 D-6
8001 4.3a(0)  5.0 (0) 5.0 (0) 3.3 (0) 1.0 (1:80) 1.0 (1:320)
8002 4.7 (0) 5.5 (0) 5.2 (0) 3.5 (0) 2.5 (1:40) 0 (1:320)
8003 5.3 (0) 5.3 (0) 5.0 (0) 3.5 (0) 2.5 (1:40) 0 (1:320)
8004 2.0 (0) 5.0 (0)  5.0 (0)  4.3 (0) 2.5 (1:40) 1.0 (1:160)
8005 4.0 (0) 5.0 (0) 5.5 (0) 3.7 (0) 1.7 (1:80) 1.0 (1:320)
8006 4.6 (0) 5.2 (0) 5.7 (0) 4.3 (0) 2.7 (1:80) 0 (1:320)
8007 4.3 (0) 5.7 (0) 4.6 (0) 4.0 (0) 2.0 (1:80) 1.0 (1:320)
8008 4.2 (0) 5.8 (0) 4.8 (0) 1.8 (0) 2.0 (1:80) 0 (1:320)
8009 5.2 (0) 5.2 (0) 5.0 (0) 3.2 (0) 2.8 (1:80) 0 (1:320)
8010 4.7 (0) 4.7 (0) 5.5 (0) 3.5 (0) 1.8 (1:80) 0.7 (1:320)
Mean 4.3 5.2 5.1 3.5 2.1 0.5
SD 0.92 0.34 0.34 0.71 0.54 0.50
aWNV titer expressed as log10 TCID50/mL of blood. 0 <0.7. (HI antibody titer; 0 <1:20)
Figure. Summary of mean (±SD) West Nile virus (WNV) titers in daily
blood samples from four groups of 10 hamsters each (control, Japa-
nese encephalitis virus [JEV]-immune, St. Louis encephalitis virus
[SLEV]-immune, and Yellow fever virus [YFV]-immune) after intraperi-
toneal inoculation of 104 tissue culture infective dose (TCID)50 of WNV.
Mean virus titers are expressed as log10 TCID50/mL of blood.RESEARCH
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Infection of SLEV-Immune Hamsters with WNV
The Figure and Table 5 summarize the results of another
experiment in which 32 adult hamsters were given a single SC
injection of approximately 106 TCID50 of SLEV strain BeAr
23379. This wild-type SLEV strain was selected for immuni-
zation, since it is not lethal to hamsters. Thirty-two days after
injection with SLEV, the animals were inoculated IP with 104
TCID50 of WNV. After this WNV challenge, the hamsters
were bled daily for 6 consecutive days, as before. Antibody
determinations were also done on blood samples taken 6 days
after challenge with WNV. 
Titration of daily blood samples from the SLEV-immune
hamsters gave results similar to those in the JEV-immune ani-
mals. After challenge with WNV, 7 of the 10 SLEV-immune
hamsters had brief, low-level viremia (Figure). However, three
hamsters had no detectable viremia.
Serologic studies on blood samples taken 30 days after
SLEV infection indicated that all the tested animals had been
infected (Table 5). The HI response at 30 days was characteris-
tic of primary Flavivirus infection. Six days after WNV infec-
tion, HI antibody titers had increased, indicating a secondary
flavivirus antibody response. As with the JEV-immune ham-
sters, the IgM response of the SLEV-immune animals was
minimal following the second flavivirus (WNV) infection
(Tables 4,5). 
Consistent with the low levels of WNV viremia (Figure),
all the SLEV-immune hamsters (n = 32) survived subsequent
challenge with WNV (Table 3). These animals did not appear
clinically ill. These results indicate that prior immunity to
SLEV also protected the hamsters from WNV encephalitis
and death. 
Infection of YFV-Immune Hamsters with WNV
Based on the results obtained with JEV- and SLEV-
immune hamsters, we tested the effect of prior immunization
with a non-JEV serocomplex Flavivirus on subsequent WNV
infection. Accordingly, a group of 30 hamsters was inoculated
IP with 106.0 TCID50 of the live attenuated 17D YFV strain.
Thirty days after immunization, nine of the animals were bled
and tested for HI antibodies to YFV and WNV (Table 6). Six
days later (36 days after 17D vaccination), the hamsters were
inoculated IP with 104 TCID50 of WNV. Ten of these animals
were bled daily for 6 consecutive days to determine the level of
viremia and subsequent antibody response (Figure) (Table 6). 
Following challenge with WNV, YFV-immune hamsters
had an intermediate level of viremia (Figure). The mean WNV
titers in the YFV-immune hamsters were higher than in the
Table 2. Serologic response of adult hamsters to West Nile virus 
(WNV), Yellow fever virus (YFV), St. Louis encephalitis virus (SLEV), 
and Japanese encephalitis virus (JEV) antigens, at various intervals 
after intraperitoneal inoculation of 104.0 TCID50 of WNV 
Animal no.
HI antibody titer
WN 
MAC-ELISA WNV YFV SLEV JEV
Day 6
8251(Da)1 : 4 00 b 0 0 0.633c
8252 1:80 0 0 0 1.013
8253(D) 1:160 0 0 0 0.878
8254 1:160 0 0 0 1.090
8255 1:80 0 0 0 0.848
8256 1:80 0 0 0 0.840
8257(D) 1:160 0 0 0 1.291
8258 1:80 0 0 0 0.869
8259(D) 1:160 0 0 0 0.939
8260 1:80 0 0 0 0.992
8262 1:80 0 0 0 0.748
8263 1:80 0 0 0 0.797
8264(D) 1:80 0 0 0 0.827
Day 31
8252 1:1,280 1:320 1:320 1:320 0.401
8254 1:1,280 1:320 1:320 1:320 0.427
8255 1:640 1:160 1:320 1:160 0.488
8256 1:640 1:160 1:160 1:160 0.582
8258 1:640 1:160 1:160 1:160 0.376
8260 1:1,280 1:320 1:320 1:320 0.420
8262 1:1,280 1:320 1:320 1:320 0.246
Day 60
8252 1:2,560 1:640 1:640 1:640 0.269
8255 1:2,560 1:640 1:640 1:640 0.216
8256 1:640 1:160 1:160 1:160 0.162
8258 1:1,280 1:320 1:320 1:320 0.161
8260 1:320 1:80 1:80 1:40 0.179
8262 1:640 1:160 1:160 1:160 0.181
Day 90
8260 1:640 1:80 1:80 1:80 0.217
8262 1:640 1:80 1:160 1:160 0.184
a(D): Hamster died of encephalitis 7 to 14 days after infection. HI = hemagglutination 
inhibition.
b0 <1:20.
cOptical density value (>0.200 is positive). 
Table 3. Infection and mortality rates, following intraperitoneal inocu-
lation of 104 TCID50 of West Nile virus (WNV), in nonimmune (con-
trol) hamsters, and in hamsters previously immunized with Japanese 
encephalitis (JE) SA14-2-8 vaccine, St. Louis encephalitis virus 
(SLEV) strain BeAr 23379, or yellow fever (YF) 17D vaccine 
Immune group
No. infected 
with WNV No. infected (%)a No. died (%)
Nonimmune 30 30 (100) 14 (47)
JEV SA14-2-8 30 30 (100) 0 (0)
SLEV BeAr 23379 32 32 (100) 0 (0)
YFV 17D 30 30 (100) 4 (13)
a Total number of animals infected or dead after being infected with WNV.Emerging Infectious Diseases  •  Vol. 8, No. 3, March 2002 249
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JEV- and SLEV-immune groups, but the titers were lower than
in the Flavivirus-naïve (control) hamsters. The death rate in
the YFV-immune hamsters was also lower; 4 (13%) of 30
YFV-immune hamsters died after challenge with WNV, com-
pared with 47% in the control group (Table 3). 
The HI antibody response after vaccination with YFV 17-
D virus (Table 6) was less intense than the primary antibody
responses to the other three flaviviruses (Tables 1,2,4,5).
Monath (26,34) also observed that immunization with 17-D
virus induces a weaker HI and complement-fixing antibody
response than infection with a wild-type YFV strain. Nonethe-
less, 6 days after challenge with WNV, the animals previously
immunized with 17-D virus demonstrated a strong secondary-
type Flavivirus antibody response. Interestingly, the 17-D
immune animals also had a stronger IgM response to WNV
infection. These data indicate that 17-D vaccine gives only
partial protection against challenge with WNV. 
Discussion
The results of these hamster studies provide new informa-
tion that may be useful in predicting the eventual geographic
spread and public health importance of WNV in the Americas,
as well as in developing novel methods for its control. The
results also demonstrate the difficulty in making a serologic
diagnosis of WNV infection in human or animal populations
exposed to other flaviviruses. 
First, our results clearly demonstrate that prior infection
(and immunity) to JEV and SLEV protects hamsters from fatal
WNV encephalitis (Table 3) and diminishes the severity of
WNV infection (Figure). Other investigators (17-20) have
reported similar findings in experimentally infected hamsters,
pigs, and monkeys. The SA14-2-8 JEV strain used in our stud-
ies is one of several live attenuated JEV vaccines originally
derived from the JEV SA14 wild-type parent strain (35,36);
two of these vaccine derivatives, SA14-2-8 and SA14-14-2,
have been widely used in China to immunize humans, equines,
and pigs (24,25,35). Consequently, considerable information is
already available on their biological and genetic characteris-
tics, immunogenicity, safety, efficacy, and duration of immu-
nity (24,25,35-37). The SA14 vaccine derivatives were
obtained by serial passage (>100 times) in primary hamster
kidney (PHK) cell cultures. Because the PHK cell substrate
has not been approved by the World Health Organization as a
vaccine substrate for use in humans, it is doubtful that the
SA14 vaccine derivatives could be used in people in the
United States or in other western countries. However, SA14-2-
8 live attenuated JEV vaccine has been used successfully in >1
million horses in China (BQ Chen, pers. comm.) (25), and
potentially it could be used in equines in the United States to
protect against WNV encephalitis. 
Table 4. Serologic response of hamsters following immunization with the SA14-2-8 vaccine strain of Japanese encephalitis virus (JEV) and sub-
sequent challenge with West Nile virus (WNV)
Hamster no.
HI antibody 30 days after 
JEV immunization
HI antibody 6 days 
after WNV challenge
WN MAC-ELISA 6 days 
after WNV challenge
8236 1:80 1:80 1:640 1:640 0.166a
8237 1:40 1:80 1:320 1:320 0.205
8238 1:80 1:80 1:640 1:640 0.239
8239 1:80 1:80 1:640 1:640 0.173
8240 1:80 1:80 1:640 1:640 0.245
8241 1:80 1:80 1:320 1:640 0.271
8242 1:80 1:80 1:1,280 1:1,280 0.209
8243 1:40 1:80 1:160 1:160 0.205
8244 1:40 1:80 1:320 1:320 0.229
8245 1:80 1:80 1:160 1:160 NT
aOptical density value (>Š0.200 is positive).
HI = hemagglutination inhibition. NT = not tested.
Table 5. Serologic response of hamsters following infection with St. 
Louis encephalitis virus (SLEV) strain Be Ar 23379 and subsequent 
challenge with West Nile virus (WNV)
Hamster no.
HI antibody 30 days 
after SLEV infection
HI antibody titer 6 
days after 
WNV challenge
WN MAC-
ELISA 6 days 
after WNV 
challenge
8276 NT NT 1:320 1:640 0.202a
8277 NT NT 1:320 1:640 0.185
8278 1:80 1:80 1:160 1:160 0.141
8279 1:80 1:80 1:160 1:160 0.165
8280 1:80 1:80 1:640 1:640 0.276
8281 1:40 1:20 1:640 1:640 0.555
8282 1:80 1:40 1:160 1:80 0.177
8283 1:80 1:80 1:160 1:160 0.166
8298 1:160 1:80 1:320 1:320 0.139
8299 1:320 1:320 1:640 1:640 0.240
NT = not tested. HI = hemagglutination inhibition.
aOptical density value (>0.200 is positive).RESEARCH
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We are testing a commercial inactivated JEV vaccine (JE-
VAX) that is already licensed for human use in the United
States. If the licensed inactivated JEV vaccine protects ham-
sters in a manner similar to the SA14-2-8 attenuated vaccine, it
might be considered as an interim WNV vaccine for groups of
humans at high risk of exposure, such as laboratory workers
and veterinarians, to protect against WNV encephalitis until a
specific WNV vaccine is available. Several potential human
WNV vaccines are now under development (38,39); however,
it will probably be years before the testing and approval pro-
cess is completed and they are licensed for human use. 
A second potentially important finding from our hamster
studies was that animals previously infected with JEV or
SLEV viruses had a much lower viremia on challenge with
WNV, compared with nonimmune animals (Table 1) (Figure).
If a similar reduction in the level of viremia occurred in JEV-
and SLEV-immune animals of other species (i.e., birds and
pigs), such animals would probably be inefficient amplifying
hosts for WNV virus. Interference from heterologous antibod-
ies to other JEV-serocomplex viruses in birds and other verte-
brate hosts may help explain the unique and largely
nonoverlapping geographic distribution of the various mem-
bers of this medically important Flavivirus complex (40,41).
To date, the spread of WNV in North America has been lim-
ited to areas that are largely free of other endemic JEV com-
plex flaviviruses (41-43). However, as WNV moves into South
Florida and the Gulf Coast or into the Midwest, regions where
SLEV is endemic (43), WNV could be restricted by heterolo-
gous antibodies to SLEV in the resident avian population.
SLEV is also endemic in tropical America (44), so potentially
the spread of WNV into that region might also be restricted for
the same reason. It will be interesting to observe how this nat-
ural experiment unfolds. 
A third important finding of our study concerns the diffi-
culty in making a serologic diagnosis of recent WNV infec-
tion. The antigenic cross-reactivity of Flavivirus antibodies is
well known, especially after a second or sequential Flavivirus
infection in the same host (11-15). As noted, until now most
WNV infections in humans and animals in North America
have occurred in areas largely free of SLEV. In the northeast-
ern region of the United States, serologic diagnosis of recent
WNV infection has been relatively easy, since most people and
animals were experiencing their first Flavivirus infection.
However, as WNV spreads into geographic regions where
people and animals have other preexisting Flavivirus antibod-
ies (i.e., SLEV, YFV, DENV), the interpretation of HI, MAC-
ELISA, and even neutralization test results will be more diffi-
cult. As we have shown (Tables 4, 5, and 6), hamsters with
prior immunity to JEV, SLEV, or YFV had a broadly reacting
HI antibody response after a second (sequential) WNV infec-
tion. Most of the JEV- and SLEV-immune hamsters did not
develop specific IgM antibodies after WNV infection. Conse-
quently, the WNV MAC-ELISA also may be of little diagnos-
tic value in such human or animal cases. The HI test and
MAC-ELISA are the two serologic tests most commonly used
by public health and veterinary diagnostic laboratories in the
United States to screen for WNV infection (42). Our data sug-
gest that these tests may give equivocal results in regions
where more than one Flavivirus is active and that other, more
specific diagnostic techniques are needed. 
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